{"generic":"Tocilizumab","drugs":["Actemra","Tocilizumab"],"mono":{"0":{"id":"929559-s-0","title":"Generic Names","mono":"Tocilizumab"},"1":{"id":"929559-s-1","title":"Dosing and Indications","sub":[{"id":"929559-s-1-4","title":"Adult Dosing","mono":"<ul><li>a baseline absolute neutrophil count (ANC) of 2000\/mm(3) or greater and a platelet count of 100,000\/mm(3) or greater are required before initiating tocilizumab<\/li><li>do not initiate tocilizumab in patients with baseline ALT or AST levels greater than 1.5 x ULN<\/li><li><b>Rheumatoid arthritis (Moderate to Severe), In patients who had an inadequate response to disease modifying antirheumatic therapy:<\/b> 4 mg\/kg IV infusion over 1 hour every 4 weeks; increase to 8 mg\/kg every 4 weeks based on clinical response; doses exceeding 800 mg per infusion are not recommended<\/li><li><b>Rheumatoid arthritis (Moderate to Severe), In patients who had an inadequate response to disease modifying antirheumatic therapy:<\/b> weight less than 100 kg, 162 mg SUBQ every other week; increase to 162 mg SUBQ every week based on clinical response<\/li><li><b>Rheumatoid arthritis (Moderate to Severe), In patients who had an inadequate response to disease modifying antirheumatic therapy:<\/b> weight 100 kg or greater, 162 mg SUBQ every week<\/li><li><b>Rheumatoid arthritis (Moderate to Severe), In patients who had an inadequate response to disease modifying antirheumatic therapy:<\/b> switching from IV to subQ, give the first subQ dose instead of the next scheduled IV dose<\/li><\/ul>"},{"id":"929559-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>a baseline absolute neutrophil count (ANC) of 2000\/mm(3) or greater and a platelet count of 100,000\/mm(3) or greater are required before initiating tocilizumab<\/li><li>do not initiate tocilizumab in patients with baseline hepatic impairment (ALT or AST elevations greater than 1.5 x ULN)<\/li><li>safety and effectiveness not established in pediatric patients younger than 2 years for the treatment of active systemic juvenile idiopathic arthritis or polyarticular juvenile idiopathic arthritis<\/li><li>change in pediatric dose should not be made based solely on weight measurement during a single visit<\/li><li><b>Juvenile idiopathic arthritis:<\/b> (less than 30 kg) 12 mg\/kg IV infusion over 1 hour once every 2 weeks<\/li><li><b>Juvenile idiopathic arthritis:<\/b> (30 kg or greater) 8 mg\/kg IV infusion over 1 hour once every 2 weeks<\/li><li><b>Polyarticular juvenile rheumatoid arthritis:<\/b> (less than 30 kg) 10 mg\/kg IV infusion over 1 hour once every 4 weeks<\/li><li><b>Polyarticular juvenile rheumatoid arthritis:<\/b> (30 kg or greater) 8 mg\/kg IV infusion over 1 hour once every 4 weeks<\/li><\/ul>"},{"id":"929559-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, mild:<\/b> no dose adjustment is required<\/li><li><b>serious infection:<\/b> hold therapy until infection is controlled<\/li><li><b>(juvenile idiopathic arthritis, polyarticular or systemic) neutropenia:<\/b> absolute neutrophil count (ANC) 500 to 1000\/mm(3), interrupt tocilizumab therapy and adjust dose of or discontinue concomitant therapy as appropriate; ANC less than 500\/mm(3), discontinue tocilizumab<\/li><li><b>(juvenile idiopathic arthritis, polyarticular or systemic) thrombocytopenia:<\/b> platelet count 50,000 to 100,000\/mm(3), interrupt tocilizumab therapy and adjust dose of or discontinue concomitant therapy as appropriate; platelet count less than 50,000\/mm(3), discontinue tocilizumab<\/li><li><b>(juvenile idiopathic arthritis, polyarticular or systemic) hepatic toxicity:<\/b> ALT or AST elevations greater than 3 to 5 x ULN, interrupt tocilizumab therapy and adjust dose of or discontinue concomitant therapy as appropriate; ALT or AST) elevations greater than 5 x ULN, discontinue tocilizumab<\/li><li><b>(adult rheumatoid arthritis) neutropenia:<\/b> for absolute neutrophil count (ANC) greater than 1000\/mm(3), maintain dosage; for ANC 500 to 1000\/mm(3), hold therapy until ANC is greater than 1000\/mm(3) and then resume IV dose at 4 mg\/kg or subQ frequency at every other week, increase IV dose to 8 mg\/kg or subQ frequency to every week as clinically appropriate; for ANC below 500\/mm(3), discontinue therapy<\/li><li><b>(adult rheumatoid arthritis) thrombocytopenia:<\/b> for platelet count 50,000 to 100,000\/mm(3), hold therapy until platelet count is greater than 100,000\/mm(3) and then resume IV dose at 4 mg\/kg or subQ frequency at every other week, increase IV dose to 8 mg\/kg or subQ frequency to every week as clinically appropriate; for platelet count less than 50,000\/mm(3), discontinue therapy<\/li><li><b>(adult rheumatoid arthritis) hepatic toxicity, ALT or AST elevations greater than 1 to 3 x ULN:<\/b> dose modify concomitant disease-modifying antirheumatic drug (DMARD) if appropriate; for persistent elevations, reduce tocilizumab IV dose to 4 mg\/kg, reduce subQ injection frequency to every other week, or hold therapy until liver enzymes normalize; resume subQ administration every other week and increase frequency to every week as clinically appropriate<\/li><li><b>(adult rheumatoid arthritis) hepatic toxicity, ALT or AST elevations greater than 3 to 5 x ULN:<\/b> hold tocilizumab therapy until liver enzymes are less than 3 x ULN and then follow recommendations for elevations greater than 1 to 3 x ULN; for persistent elevations greater than 3 x ULN, discontinue tocilizumab<\/li><li><b>(adult rheumatoid arthritis) hepatic toxicity, ALT or AST elevations greater than 5 x ULN:<\/b> discontinue tocilizumab<\/li><\/ul>"},{"id":"929559-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Juvenile idiopathic arthritis<\/li><li>Polyarticular juvenile rheumatoid arthritis<\/li><li>Rheumatoid arthritis (Moderate to Severe), In patients who had an inadequate response to disease modifying antirheumatic therapy<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Rheumatoid arthritis (Moderate to Severe), with no previous treatment failure<br\/>"}]},"2":{"id":"929559-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Solution)<\/b><br\/>Patients treated with tocilizumab are at increased risk for infections, some progressing to serious infections leading to hospitalization or death. These infections have included bacterial infection, tuberculosis, invasive fungal, or other opportunistic infections. Evaluate for latent tuberculosis and treat if necessary prior to initiation of therapy. Monitor patients receiving tocilizumab for signs and symptoms of infection, including tuberculosis, even if initial latent tuberculosis test is negative.<br\/><\/li><li><b>Subcutaneous (Solution)<\/b><br\/>Patients treated with tocilizumab are at increased risk for infections, some progressing to serious infections leading to hospitalization or death. These infections have included bacterial infection, tuberculosis, invasive fungal, or other opportunistic infections. Evaluate for latent tuberculosis and treat if necessary prior to initiation of therapy. Monitor patients receiving tocilizumab for signs and symptoms of infection, including tuberculosis, even if initial latent tuberculosis test is negative.<br\/><\/li><\/ul>"},"3":{"id":"929559-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929559-s-3-9","title":"Contraindications","mono":"known hypersensitivity to tocilizumab <br\/>"},{"id":"929559-s-3-10","title":"Precautions","mono":"<ul><li>serious infections (eg, TB, invasive fungal infections, and other opportunistic infections), including fatalities, have been reported, especially with concomitant immunosuppressant use; do not initiate therapy in patients with active infections (including chronic or localized infections); monitoring recommended; interrupt therapy if a serious infection develops<\/li><li>TB, reactivation or new onset, may occur; increased risk in patients with potential exposure due to travel or residence in endemic areas, close personal contact with active TB, or with history of latent or active disease; monitoring recommended<\/li><li>concomitant use of biological disease-modifying antirheumatic drugs, such as tumor necrosis factor (TNF) antagonists, interleukin-1R antagonists, anti-CD20 monoclonal antibodies and selective co-stimulation modulators, should be avoided<\/li><li>concomitant use with live vaccines should be avoided<\/li><li>demyelinating disorders (eg, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy) have been reported; exercise caution in patients with preexisting or recent onset demyelinating disorders; monitoring recommended<\/li><li>gastrointestinal perforation has been reported<\/li><li>geriatric (65 years and older); higher frequency of serious infections have been reported<\/li><li>hematologic abnormalities (eg, neutropenia and thrombocytopenia) have been reported; monitoring recommended; interruption, dose reduction, and discontinuation may be necessary<\/li><li>hepatic impairment or active hepatic disease; use not recommended<\/li><li>hepatic transaminase (AST and ALT) elevations have been reported; increased frequency and magnitude observed with concomitant use of hepatotoxic drugs; monitoring recommended; interruption, dose reduction, and discontinuation may be necessary<\/li><li>hypersensitivity reactions, including anaphylaxis, have been reported and fatalities have been reported with IV administration; if an anaphylactic or hypersensitivity reaction occurs, permanently discontinue treatment<\/li><li>lipid elevation, including total cholesterol, triglyceride, and LDL cholesterol, has occurred; monitoring recommended<\/li><li>malignancies have been reported<\/li><li>report suspected adverse reactions to Genentech at 1-888-835-2555 or the US Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929559-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"929559-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929559-s-4","title":"Drug Interactions","sub":{"1":{"id":"929559-s-4-14","title":"Major","mono":"<ul>Infliximab (theoretical)<\/ul>"}}},"5":{"id":"929559-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (adults, 4% to 6%)<\/li><li><b>Dermatologic:<\/b>Injection site reaction (Rheumatoid arthritis, 2.4% to 10.1%), Rash (Rheumatoid arthritis, 2% to 4%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (Children, greater than 5%), Upper abdominal pain (Adults, 2% to 3%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (Rheumatoid arthritis, 0.7% to 48%; polyarticular or systemic juvenile idiopathic arthritis, 4% to 13%), AST\/SGOT level raised (Rheumatoid arthritis, 0.1% to 41%; polyarticular or systemic juvenile idiopathic arthritis, less than 1% to 5%)<\/li><li><b>Neurologic:<\/b>Dizziness (adults, 2% to 3%), Headache (adults, 5% to 7%; children, greater than 5%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (rheumatoid arthritis, 4% to 7%; systemic juvenile idiopathic arthritis, 5% or higher)<\/li><li><b>Other:<\/b>Infusion reaction (Rheumatoid arthritis, 7% to 8%; polyarticular juvenile idiopathic arthritis, 16% to 20.2%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Gastrointestinal perforation<\/li><li><b>Hematologic:<\/b>Decreased platelet count (1% to 4%), Neutropenia (rheumatoid arthritis, 1.8% to 3.7%; polyarticular or systemic juvenile idiopathic arthritis, 3.7% to 17%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction (0% to 0.9%), Opportunistic infection, Tuberculosis<\/li><li><b>Respiratory:<\/b>Upper respiratory infection (rheumatoid arthritis, 6% to 8%; systemic juvenile idiopathic arthritis, 5% or higher)<\/li><li><b>Other:<\/b>Cancer, Severe infectious disease<\/li><\/ul>"},"6":{"id":"929559-s-6","title":"Drug Name Info","sub":{"0":{"id":"929559-s-6-17","title":"US Trade Names","mono":"Actemra<br\/>"},"2":{"id":"929559-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"929559-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929559-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929559-s-7","title":"Mechanism Of Action","mono":"Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor that binds specifically to both the soluble and membrane-bound IL-6 receptors and has been shown to inhibit IL-6 mediated signaling via these receptors. IL-6 is produced by a variety of cell types including synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes such as rheumatoid arthritis.<br\/>"},"8":{"id":"929559-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929559-s-8-23","title":"Absorption","mono":"subQ, 80% <br\/>"},"1":{"id":"929559-s-8-24","title":"Distribution","mono":"<ul><li>Vd, polyarticular juvenile idiopathic arthritis: 4.08 L<\/li><li>Vd, rheumatoid arthritis: 6.4 L<\/li><li>Vd, systemic juvenile idiopathic arthritis: 2.54 L<\/li><\/ul>"},"3":{"id":"929559-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance, polyarticular juvenile idiopathic arthritis: 5.8 mL\/hr<\/li><li>Total body clearance, rheumatoid arthritis: 0.29 mL\/hr\/kg<\/li><li>Total body clearance, systemic juvenile idiopathic arthritis: 7.1 mL\/hr<\/li><\/ul>"},"4":{"id":"929559-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Polyarticular juvenile idiopathic arthritis: up to 16 days<\/li><li>Rheumatoid arthritis, up to 11 days (multiple-dose, 4 mg\/kg IV), up to 13 days (multiple-dose, 8 mg\/kg IV), 6.3 days (single-dose, 10 mg\/kg IV); up to 13 days (multiple-dose, 162 mg subQ every week); up to 5 days (multiple-dose, 162 mg subQ every other week)<\/li><li>Systemic juvenile idiopathic arthritis, up to 23 days (multiple-dose, 8 or 12 mg\/kg)<\/li><\/ul>"}}},"9":{"id":"929559-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>do not use tocilizumab for subQ injection for IV drip infusion<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>discard unused portions<\/li><li>fully diluted tocilizumab solutions are compatible with polypropylene, polyethylene, and polyvinyl chloride infusion bags, or with polypropylene, polyethylene, and glass infusion bottles<\/li><li>pediatric patients weighing less than 30 kg: from a 50 mL infusion bag or bottle remove a volume of liquid equal to the volume of the tocilizumab solution for the patient's dose; slowly add tocilizumab to infusion bag or bottle; mix gently to avoid foaming<\/li><li>pediatric patients weighing 30 kg or greater: from a 100 mL infusion bag or bottle remove a volume of liquid equal to the volume of the tocilizumab solution for the patient's dose; slowly add tocilizumab to infusion bag or bottle; mix gently to avoid foaming<\/li><li>adult patients: from a 100 mL infusion bag or bottle remove a volume of liquid equal to the volume of the tocilizumab solution for the patient's dose; slowly add tocilizumab to infusion bag or bottle; mix gently to avoid foaming<\/li><li>diluted solution may be stored at 2 to 8 degrees C (36 to 46 degrees F) for up to 24 hours<\/li><li>protect diluted solution from light<\/li><li>allow diluted solution to reach room temperature before infusion<\/li><li>administer as IV infusion over 60 minutes (must use an infusion set); do not administer as IV push or IV bolus<\/li><li>do not infuse with other drugs in the same IV line<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>prefilled syringe is for single use only<\/li><li>rotate injection sites with each injection; do not administer into areas of tender, bruised, red, hard, or scarred skin, skin that is not intact, or moles<\/li><\/ul><\/li><\/ul>"},"10":{"id":"929559-s-10","title":"Monitoring","mono":"<ul><li>normalization of serum C-reactive protein levels and reduction in pain and in tender and swollen joint counts are indicative of efficacy<\/li><li>lipid parameters; at approximately 4 to 8 weeks following initiation of therapy and every 6 months thereafter<\/li><li>polyarticular juvenile idiopathic arthritis: neutrophil and platelet counts; at the time of second infusion and every 4 to 8 weeks thereafter.<\/li><li>polyarticular juvenile idiopathic arthritis: ALT and AST levels; at the time of second infusion and every 4 to 8 weeks thereafter.<\/li><li>rheumatoid arthritis: absolute neutrophil and platelet counts; every 4 to 8 weeks after therapy initiation and every 3 months thereafter<\/li><li>rheumatoid arthritis: ALT and AST levels; every 4 to 8 weeks after therapy initiation and every 3 months thereafter; other liver function tests, such as bilirubin; when clinically indicated<\/li><li>systemic juvenile idiopathic arthritis: absolute neutrophil and platelet counts; at the time of second infusion and every 2 to 4 weeks thereafter<\/li><li>systemic juvenile idiopathic arthritis: ALT and AST levels at the time of second infusion and every 2 to 4 weeks thereafter<\/li><li>signs and symptoms of infection, including tuberculosis; during and after treatment<\/li><li>signs and symptoms of demyelinating disorders<\/li><\/ul>"},"11":{"id":"929559-s-11","title":"How Supplied","mono":"<b>Actemra<\/b><br\/><ul><li>Intravenous Solution: 20 MG\/ML<\/li><li>Subcutaneous Solution: 162 MG\/0.9 ML<\/li><\/ul>"},"13":{"id":"929559-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that live vaccines must be avoided during therapy due to drug-induced immunosuppression.<\/li><li>Instruct patient to notify doctor immediately with symptoms of an infection including reactivation of TB, herpes zoster, or hepatitis B.<\/li><li>Side effects may include nasopharyngitis, upper respiratory tract infection, headache, hypertension, and injection site reactions.<\/li><li>Instruct patient to report symptoms of a gastrointestinal perforation.<\/li><li>If appropriate, teach patient the proper technique and placement of subQ injections.<\/li><\/ul>"}}}